Galderma, L’Oréal announce scientific-based partnership

Galderma and L’Oréal are coming together to work on a new research and development partnership. 

Focused on developing advanced, future-proof technologies with direct applications in dermatology, the two companies will focus on findings related to the fight against the signs of skin aging. 

“We are on a journey of growth, innovation and leadership in the field of dermatology, powered by our unique integrated model. As we continue to deliver outstanding performance across our blockbuster platforms in attractive dermatology market segments, our commitment to progressing our current late-stage pipeline and advancing science and innovation remain a cornerstone of our approach,” said Flemming Ørnskov, chief executive officer at Galderma. “We are delighted to welcome L’Oréal as a new, long-term Galderma shareholder and see their investment as a sign of confidence in our strategy, track record and growth potential. We look forward to pursuing scientific partnership opportunities together, for the benefit of the customers, patients and consumers we serve across the globe every day.”

[Read more: Naomi Watts’ Stripes Beauty acquired by L Catterton]

L’Oréal also announced an agreement between Sunshine SwissCo AG, Abu Dhabi Investment Authority and Auba Investment Pte., acting as sellers, and L’Oréal Group for the sale of a 10% stake in Galderma Group AG at an undisclosed premium.

“This transaction is part of our strategy to continue supporting Galderma on its outstanding growth journey in the attractive dermatology market. We remain committed to Galderma and will continue managing our investment in the best interest of all its shareholders. Selling a minority stake to a reputable strategic partner such as L’Oréal, the global leader in Beauty, is a direct reflection of our commitment,” said Michael Bauer, partner and co-head of the global healthcare sector at EQT.